Aza-BFcell-106

Aza-BFcell-106 is a **whole-tumor-cell cancer vaccine** created by stimulating B16-F10 melanoma cells with low-dose 5-azacytidine (Aza) to upregulate toll-like receptor 3 (TLR3) expression, followed by surface conjugation with SZU-106, a small-molecule TLR7 agonist, via a pegylated linker[1]. The cells are then **inactivated by UV irradiation**, producing a vaccine containing a full spectrum of tumor antigens and enhanced immune-stimulatory capacity. In preclinical studies, Aza-BFcell-106 promoted the maturation of dendritic cells, robust cytokine release (e.g., IFN-γ, IL-6, TNF-α), and potent activation of antitumor immunity, leading to inhibited tumor growth and prolonged survival in melanoma mouse models. Combination with the chemokine inhibitor reparixin further heightened antitumor effects via increased T-cell infiltration[1]. The vaccine is intended as an immunotherapy for advanced malignant tumors, with an approach that enables relatively rapid personalization from patient-derived tumor samples[1].